Bart Eeckhaut

Dr. Bart Eeckhaut

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
BEBart Eeckhaut
Bart Eeckhaut
STSteven Truijen
Steven Truijen
CLCaroline Leroij
Caroline Leroij
JDJuliette Dévillé
Juliette Dévillé
LJLisa Jacobs
Lisa Jacobs
WSWim Saeys
Wim Saeys
Background/Objectives: In the past few years increasing attention has been given to the application of dry needling (DN) for spasticity in stroke survivors. Nevertheless, the underlying mechanisms of this technique have not yet been confirmed. The aim of this systematic review was to distinguish the effects of DN in post-stroke spasticity on both structural–mechanical muscle properties (SMMPs) and neurophysiological properties to address these mechanisms. Methods: A literature search was performed in Web of Science, PubMed, Scopus and Embase following PRISMA guidelines (PROSPERO ID: 1163064). Randomized controlled trials and case–control studies involving adults with post-stroke spasticity treated with DN were included. Outcomes were categorized as SMMPs (e.g., muscle architecture, passive stiffness, PROM) or neurophysiological measures (e.g., H-reflex, H/M ratio). Standardized effect sizes (Hedges’ g) were calculated when possible; however, heterogeneity in outcomes and incomplete variance reporting precluded meta-analysis. Results: Twelve studies met the inclusion criteria. Most of these studies assessed passive range of motion, reporting a significant increase following the intervention. Only two of the included studies examined structural characteristics, and five studies included neurophysiological outcomes. Correlations between mechanistic outcomes and clinical spasticity grading (MAS/MMAS) were weak. Emerging evidence suggests DN may additionally modulate local inflammatory mediators, indicating a potential neuroimmune contribution to its effects. Conclusions: DN appears to improve structural–mechanical muscle properties and produce moderate reductions in reflex excitability in individuals with post-stroke spasticity. Mechanical adaptations are more consistently demonstrated than neural changes, and neither domain is proportionally reflected in clinical spasticity scales. Evidence remains limited by small samples, methodological variability, and incomplete reporting. Further mechanistic research is needed to clarify how DN influences the complex pathophysiology of post-stroke spasticity.

20 May 2026 in PLOS ONE
Verified
Journal Article
Open access
CPCLARA PUJOL
CLARA PUJOL
BEBart Eeckhaut
Bart Eeckhaut
Samuel Fernández-CarneroSamuel Fernández-Carnero
Samuel Fernández-Carnero
DSDaniel Fernández Sanchís
Daniel Fernández Sanchís
TWTheodore Wein
Theodore Wein
MLMindy F. Levin
Mindy F. Levin
Introduction: Stroke often causes spasticity, impacting mobility and quality of life. Botulinum Toxin type A (BTX-A) and Dry Needling (DN) are treatments that reduce spasticity, although Botulinum Toxin type A injections can cause adverse effects. No studies have directly compared their effects at spinal, muscular, functional, quality-of-life, and cost-effectiveness levels. This study aims to determine the spinal mechanisms of BTX-A and DN on post-stroke lower limb spasticity, while also assessing feasibility, safety, and exploratory effects at muscular, functional, quality-of-life, and cost-effectiveness levels. Methods and analysis: This is a protocol of a proof-of-concept, feasibility randomized clinical trial including 90 participants from Canada, Belgium, and Spain who experienced a first stroke in the previous 12 months and present plantar flexor spasticity. Time since stroke (0–12 months) will be recorded and explored as a potential modifier of treatment response. Participants will be randomly assigned to receive either one session of BTX-A or 12 weekly sessions of DN. Blinded evaluators will assess outcomes before, during, and after treatment, with a 4-week follow-up. The primary outcome will be spinal mechanisms of spasticity, measured using the Tonic Stretch Reflex Threshold and its velocity sensitivity. Secondary outcomes will assess: a) muscular architecture and echotexture (measured with ultrasound); b) muscle tone/resistance using the Modified Ashworth Scale; c) gait and mobility (instrumented analysis, Timed Up and Go, 10-Meter Walk Test); d) muscle strength with dynamometry; e) quality of life with the EuroQoL questionnaire; and f) cost-effectiveness (analytic model). The findings will provide preliminary data to inform a future definitive trial. Ethics and Dissemination: This research project has secured funding from the NEURON ERA-NET 2022 call, supported by the European Union’s Horizon 2020 program (GA 964215) and co-funded by the European Union-Next Generation, and has undergone peer review. Ethical approval has been obtained from Spain, Canada, and Belgium. The study is registered in ClinicalTrials.gov (NCT06296082) and the Clinical Trials Information System (CTIS) under the number 2024-510866-18-00. The study protocol is registered on Zenodo ( https://doi.org/10.5281/zenodo.20034064 ) Clinical Trials: Clinical Trials NCT06296082; https://clinicaltrials.gov/study/NCT06296082

20 September 2026 in Toxins
Verified
Journal Article
Open access
PDF file
BEBart Eeckhaut
Bart Eeckhaut
STSteven Truijen
Steven Truijen
PHParham Haghshenas
Parham Haghshenas
ARAntriana Roussou
Antriana Roussou
PTPetros Taflampas
Petros Taflampas
WSWim Saeys
Wim Saeys
Background: Botulinum toxin type A (BoNT-A) is globally recognized as a standard treatment for post-stroke spasticity (PSS), although its secondary mechanisms remain underinvestigated. The objective of this study was to investigate the neurophysiological mechanisms underlying BoNT-A treatment in PSS and explore their implications for mechanism-based rehabilitation. Methods: A systematic review and meta-analysis (PROSPERO registration number ID: CRD420261352230) of 39 studies involving 760 patients was conducted on 18 August 2026, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed, Web of Science, Scopus, and Embase were systematically searched using the PICO framework. Where possible, quantitative data were pooled according to predefined neurophysiological constructs, including passive stretch-evoked activity, voluntary activation of the injected muscle, compound muscle action potential (CMAP), reciprocal motor control, normalized Hmax/Mmax, and specific spinal inhibitory mechanisms. Results: Quantitative synthesis demonstrated construct-specific neurophysiological changes following BoNT-A treatment. Passive stretch-evoked activity showed the largest pooled effect (Hedges’ g = 0.80, 95% CI 0.35–1.24), followed by CMAP amplitude (g = 0.69, 95% CI 0.23–1.14) and reciprocal motor control (g = 0.52, 95% CI 0.23–0.81). Effects on voluntary activation of the injected muscle (g = 0.31, 95% CI −0.38 to 1.00) and normalized Hmax/Mmax (g = 0.22, 95% CI −0.74 to 1.17) were smaller and more heterogeneous. Reciprocal and recurrent inhibition were each represented by single-study estimates, while supraspinal outcomes were synthesized narratively due to methodological heterogeneity. Conclusions: The findings support a predominantly peripheral mechanism of BoNT-A while suggesting possible secondary changes within spinal and supraspinal motor control pathways. However, the certainty of evidence was low to very low. These neurophysiological effects provide a rationale for individualized, mechanism-based rehabilitation during the post-injection therapeutic window, although higher-quality evidence is required to confirm this framework.